This is a big month for $BPSR with a potential break out in a few weeks. They just finished their primary results on June 30th with July 31st estimated to be the studies completion for the whole trial. The FDA approved BPSR to have up to 60 patients to be treated to find if this could be a cure for severe / mild cases of COVID-19. They have yet to annouce the results. This all started because a fews month ago they had their first trial which was granted on 10 patients and it returned with a 100 percent effective rate. Most patients that were treated were severe cases that were hospitalized and non responsive. All patients lived and have recovered from their treatments. If Trail 2 is successful, this treatment is expected to help mild, severe and longer haulers in the future with COVID-19.

The product is called Zofin. - The property of Zofin demonstrates the therapeutic potential as a suppressor of cytokine activation for the reduction of COVID-19 infection severity - Zofin is an acellular, minimally manipulated product, derived from human amniotic fluid (HAF). - It has been suggested in published research that inhibition or suppression of this pro-inflammatory cytokine cascade may reduce the severity of symptoms associated with elevated immune response. - Furthermore, the miRNA was found to target 148 genes associated with immune response. - Ultimately Zofin is a Exosomes treatment that can be used to tackle multiple parts of the body. In this case, Zofin is helping the lungs due to reports that the treatment removes COVID-19 directly from the lungs completely.

Zofin treatment (non-covid19) and trails. - COPD (Phase1\2 Trails) - Knee Osteoarthritis (Phase1\2 Trails) - Cardiac (Pending Research) - Autoimmune (Pending Research)

About the company. - Owner (Albert Mitrani) - Miami based company - Trail Locations [Texas] - Focus on treatments [Regenerative Therapeutics] - Currently an OTC Company but currently attempting to Uplist into NASDAQ. - Current average .14 cents a share. - High of .78 cents when announcement was made of first 10 patients.

The company's goal which has been stated by Albert Mitrani if the research concluds positive. They will try to push to have Zofin release in India and Pakistan as a emergency release treatment. They have already made plans and are working with a distribution company in Pakistan. Due to this treatment having a record of approval of FDA it has a great potential to do just that.

I am here to share with everyone because this company can be a potential candidate within the next month of a break out stock. Do your DD before you make decisions and of course this is not financial advice.